CDKN2A and mature T-cell and NK-cell non-Hodgkin lymphoma: Since the frequency of p16 deletion is reported to increase as the ATLL stage progresses [28], we expected that patients with ATLL might have lower scores for p16 expression in our immunostaining analyses compared to those with PTCL-NOS.